Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ANO1 | Q5XXA6 | 10/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6581878 | 0.90 | SLC2A1 (0.47) | KDM4EANO1SLC2A1MEN1KMT2A | |
| SCHEMBL6581754 | 0.89 | SLC2A1 (0.49) | KDM4EANO1SLC2A1MEN1KMT2A | |
| SCHEMBL6579471 | 0.88 | LMNA (0.53) | KDM4EANO1MEN1KMT2AATM | |
| SCHEMBL6583854 | 0.87 | SLC2A1 (0.49) | KDM4EANO1SLC2A1ALDH1A1HPGD | |
| SCHEMBL6582262 | 0.86 | PTPN1 (0.48) | KDM4EANO1SLC2A1ALDH1A1 | |
| SCHEMBL6581560 | 0.84 | ALOX5 (0.53) | KDM4EANO1SLC2A1MEN1KMT2A | |
| SCHEMBL6582283 | 0.82 | ANO1 (0.46) | ANO1SLC2A1MEN1KMT2A | |
| SCHEMBL6579758 | 0.79 | ALOX5 (0.42) | ANO1SLC2A1LMNA | |
| SCHEMBL6582307 | 0.78 | KDM4E (0.52) | KDM4EMEN1KMT2AATMALDH1A1 | |
| SCHEMBL6580117 | 0.78 | PTPN1 (0.46) | KDM4EANO1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401822-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-31 | — | — | EP | claimed |
| US-6599925-B2 | Cardiovascular disorders; anticancer agents | WYETH | 2003-07-29 | — | — | US | claimed |
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-01-23 | — | — | US | claimed |
| WO-2003000671-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | claimed |
| EP-1401822-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6599925-B2 | Cardiovascular disorders; anticancer agents | WYETH | 2003-07-29 | — | — | US | disclosed |
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-01-23 | — | — | US | disclosed |
| WO-2003000671-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | F2R, SERPINE1, SERPINC1 | KDM4E 4021/4885ANO1 3199/4885SLC2A1 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.